The endpoint used by the Global Burden of Disease study, and used in recalibration, is described in Appendix 4 -0.0040 (-0.0085, 0.0006) 1 Calculated using an internal/eternal validation approach in which each study was in turn left out of the model fit and used in validation. C-index shown is the results of pooling the C-index from each external study. Comprison of this to the C-index calculated for remaining studies revealed no evidence for optimism in pooled C-index estimates (p>0.999 for all models). 2 Calculated by pooling the within study C-index values weighting by the number of contributing events. 3 Calculated by pooling the within study differences in C-index values obtained using the two models, weighting by the number of contributing events. 
ERFC: Emerging Risk Factors Collaboration APCSC: Asia Pacific Cohort Studies Collaboration

4) Supplementary statistical methods
Assessment of calibration within the derivation dataset
Mean predicted and observed 10-year risks were calculated and compared within deciles of predicted risk for each sex specific CHD and Stroke model separately using studies that had at least 10-years follow-up. Predicted risks were estimated using the fitted cox model using the study specific baseline survival estimates at 10-years and common hazard ratios as presented in Table 2 and Table 1 .5. Mean observed 10-year CVD risk within each decile and study ( , for decile and study in 1:S), was obtained using the following general Cox model:
where β is a vector, and d a set of dummy variables representing the deciles, | , is the probability of not having a CVD event by time t given category and study , and , is the baseline survival function for study s. Observed decile-and study-specific 10-year CVD risk was then estimated using the following translation:
This method assumes proportional hazards across deciles, and the process was completed separately for men and women. Study-specific estimates of observed risk in each decile , were pooled across studies weighting by the number of study and decile-specific contributing events: 
Methods used for recalibration
Recalibration of the core models was completed separately for each target country, sex and endpoint (MI and stroke) using the general process described in Figure 1.3 . This involved the use of country-sex-specific mean risk factor levels (from NCDRisc) and country-sex-specific estimates of annual incidence of MI and stroke events within 5-year age groups, from GBD 2017.
We used the core WHO risk models to estimate 10-year predicted risk of each endpoint for each of the age groups using the mean risk factor values ( Expected 10-year risk: 1 -exp( 10 .
(1)
Having completed this process for each age group, as shown in Figure 1.3 we then regressed transformed expected 10-year risk across age groups on that predicted by the WHO risk models to derive recalibration factors (the intercept and slope of the resulting regression line). The WHO risk models, rescaled using the recalibration factors were then used to estimate appropriate risks for each potential risk factor combination. Finally for construction of region specific 10-year CVD risk charts, the separately recalibrated risks of MI and stroke were combined using Equation 2
for each risk factor combination, where , and are the probabilities of having a MI, stroke or CVD (MI or stroke) event over the next 10-years.
1 1 * 1
( 2 )
We completed the following sensitivity analyses regarding the recalibration procedure: 1) Rather than using a single incidence rate to estimate expected risk over 10-years for each age group (Equation 1) we interpolated GBD rates obtained from the IHME to get the expected incidence at the midpoint of each 1-year risk period (say , ) and estimated expected 10-year risk as one minus probability of surviving each subsequent 1-year interval: 1 ∏ exp , ; 2) We derived a single risk model to estimate 10-year CVD risk and recalibrated this directly to CVD rates (MI + stroke incidence) rather than allowing separate models for MI and stroke components and recalibration to individual MI or stroke rates. Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point). *Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.
